Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $68,176.40 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 170,441 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $0.40, for a total transaction of $68,176.40. Following the sale, the insider owned 349,907 shares in the company, valued at approximately $139,962.80. This trade represents a 32.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. sold 149,625 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $55,361.25.
• On Monday, June 15th, Ra Capital Management, L.P. sold 128,770 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.39, for a total value of $50,220.30.
• On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.38, for a total value of $99,751.14.
• On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $16,991.51.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Trading Up 2.1%

Shares of NASDAQ:HOWL opened at $0.35 on Friday. The stock’s 50-day moving average price is $0.61 and its two-hundred day moving average price is $0.69. Werewolf Therapeutics, Inc. has a 12-month low of $0.34 and a 12-month high of $2.38. The firm has a market cap of $17.07 million, a price-to-earnings ratio of -0.28 and a beta of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. As a group, research analysts forecast that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of large investors have recently modified their holdings of the company. AQR Capital Management LLC acquired a new position in shares of Werewolf Therapeutics in the 1st quarter valued at about $79,000. Marshall Wace LLP purchased a new position in Werewolf Therapeutics in the second quarter valued at approximately $113,000. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics in the second quarter valued at approximately $48,000. Jane Street Group LLC acquired a new position in Werewolf Therapeutics during the second quarter valued at approximately $409,000. Finally, Bank of America Corp DE lifted its position in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares in the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HOWL has been the subject of several research analyst reports. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings lowered shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Werewolf Therapeutics has an average rating of “Hold” and an average target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.